Posted by Michael Wonder on 12 Jul 2023
Idefirix (imlifidase) receives provisional approval in Australia as desensitisation treatment in highly sensitised patients prior to kidney transplantation
11 July 2023 - Regulatory milestone marks the first time Idefirix has been approved in kidney transplantation from both living and deceased donors.
Hansa Biopharma today announced that the Australian TGA has provisionally approved Idefirix (imlifidase) as desensitisation treatment for highly sensitised patients prior to kidney transplantation from both living and deceased donors.
